Role of PPARγ, a nuclear hormone receptor in neuroprotection

Indian Journal of Biochemistry and Biophysics

Volumn 48, Issue 2, 2011, Pages 73-81

  Gillespie, William ^a   Tyagi, Neetu ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Alzheimer's disease; Ischemia; Multiple Sclerosis; Neurodegenerative disorder; Neuronal death; Parkinson's disease; PPAR

Indexed keywords

NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL; BRAIN ISCHEMIA; CELL DEATH; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; CYTOLOGY; DEGENERATIVE DISEASE; HUMAN; METABOLISM; NERVE CELL; PATHOLOGY; REVIEW;

ANIMALS; BRAIN ISCHEMIA; CELL DEATH; CENTRAL NERVOUS SYSTEM; CYTOPROTECTION; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; PPAR GAMMA;

EID: 84924225177     PISSN: 03011208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Tatenhorst L, Hahnen E & Heneka M T (2008) Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors. PPAR Res 204514
2. Adams M, Montague C T & Prins C J (1997) Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100, 3149-3153
3. Heneka M T & Landreth G E (2007) PPARS in the brain. Biochim Biophys Acta (BBA) - Mol Cell Biol Lipids 1771, 1031-1045
4. Desvergne B & Wahli W (1999) Peroxisome proliferatoractivated receptors: nuclear control of metabolism. Endocrine Rev 20, 649-688
5. Grommes C, Landreth G E & Heneka M T (2004) Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 4, 419-429
6. Kersten S, Desvergne B & Wahli W (2000) Roles of PPARs in health and disease. Nature 405, 421-424
7. Lemberger T, Desvergne B & Wahli W (1996) Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Ann Rev Cell Develop Biol 12, 335-363
8. Michalik L, Auwerx J, Berger J P, Chatterjee V K, Glass C K, Gonzalez F J, Grimaldi P A, Kadowaki T, Lazar M A, O'Rahilly S, Palmer C N, Plutzky J, Reddy J K, Spiegelman B M, Staels B & Wahli W (2006) International Union of Pharmacology. LXI. Peroxisome proliferatoractivated receptors. Pharmacol Rev 58, 726-741
9. Barish G D (2006) Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity. J Nutr 136, 690-694
10. Daynes R A & Jones D C (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2, 748-759
11. Armoni M, Harel C, Karni S, Chen H, Bar-Yoseph F, Ver M R, Quon M J & Karnieli E (2006) FOXO1 represses peroxisome proliferator-activated receptor-γ1 and -γ2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem 281, 19881-19891
12. Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre A M, Saladin R, Najib J, Laville M, Fruchart J C, Deeb S, Vidal-Puig A, Flier J, Briggs M R, Staels B, Vidal H & Auwerx J (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272, 18779-18789
13. Blaschke F, Takata Y, Caglayan E, Law R E & Hsueh W A (2006) Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 26, 28-40
14. Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart J C & Bastide M (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34, 1341-1346
15. Delerive P, Fruchart J C & Staels B (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169, 453-459
16. Roses A D, Saunders A M, Huang Y, Strum J, Weisgraber K H & Mahley R W (2007) Complex diseaseassociated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J 7, 10-28
17. Lehrke M & Lazar M A (2005) The many faces of PPARgamma. Cell 123, 993-999
18. Park K S, Lee R D, Kang S K, Han S Y, Park K L, Yang K H, Song Y S, Park H J, Lee Y M, Yun Y P, Oh K W, Kim D J, Yun Y W, Hwang S J, Lee S E & Hong J T (2004) Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptorgamma via the JNK-dependent pathway. Exp Cell Res 297, 424-433
19. Saluja I, Granneman L & Skoff R P (2001) PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 33, 191-204
20. Moreno S, Farioli-Vecchioli S & Ceru M P (2004) Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123, 131-145
21. Cunard R, DiCampli D, Archer D C, Stevenson J L, Ricote M, Glass C K & Kelly C J (2002) WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol 169, 6806-6812
22. Heneka M T, Klockgether T & Feinstein D L (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20, 6862-6867
23. Andersen J K (2004) Oxidative stress in neurodegeneration: cause or consequence. Nat Med 10, S18-S25
24. Feinstein D L (2003) Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 5, 67-73
25. Kim E J, Kwon K J, Park J Y, Lee S H, Moon C H & Baik E J (2002) Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 941, 1-10
26. Zhao Y, Patzer A, Herdegen T, Gohlke P & Culman J (2006) Activation of cerebral peroxisome proliferator-actiavted receptors γ promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 20, 1162-1175
27. Schütz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth G E, Schürmann B, Zimmer A & Heneka M T (2005) The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. Journal of Neuroscience 25, 7805-7812
28. Kiaei M, Kipiani K, Chen J, Calingasan N Y & Beal M F (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191, 331-336
29. Kielian T & Drew D P (2003) Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation J Neurosci Res 71, 315-325
30. Barone F C, Hillegass L M, Tzimas M N, Schmidt D B, Foley J J, White R F, Price W J, Feuerstein G Z, Clark R K & Griswold D E (1995) Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke. Mol Chem Neuropathol 24, 13-30
31. Lee J M, Grabb M C, Zipfel G J & Choi D W (2000) Brain tissue response to ischemia. J Clin Invest 106, 723-731
32. Dirnagl U, Iadecola C & Moskowitz M A (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22, 391-397
33. Zheng Z & Yenari M A (2004) Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol Res 26, 884-892
34. Iadecola C & Ross M E (1997) Molecular pathology of cerebral ischemia: delayed gene expression and strategies for neuroprotection. Ann N Y Acad Sc 835, 203-217
35. Culman J, Zhao Y, Gohlke P & Herdegen T (2007) PPARgamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 28, 244-249
36. Victor N A, Wanderi E W, Gamboa J, Zhao X, Aronowski J, Deininger K, Lust W D, Landreth G E & Sundararajan S (2006) Altered PPARγ expression and activation after transient focal ischemia in rats. Eur J Neurosci 24, 653-1663
37. 2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 26, 481-487
38. Sundararajan S, Jiang Q, Heneka M T & Landreth G (2006) PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 49, 136-144
39. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, Nagoya H & Greenberg J H (2005) A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36, 353-359
40. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa A C, Dianzani C, Danni O, Thiemermann C & Fantozzi R (2006) Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 13, 70-80
41. Pereira M P, Hurtado O, Cárdenas A, Alonso-Escolano D, Boscá L, Vivancos J, Nombela F, Leza J C, Lorenzo P, Lizasoain I & Moro M A (2005) The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol 64, 797-805
42. Lee S R, Kim H Y, Hong J S, Baek W K & Park J W (2009) PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. Biochem Biophys Res Commun 380, 17-21
43. Luo Y, Yin W, Signore A P, Zhang F, Hongs Z, Wang S, Graham S H & Chen J (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferatoractivated receptor-γ agonist rosiglitazone. J Neurochem 97, 435-448
44. Sen U, Rodriguez W E, Tyagi N, Kumar M, Kundu S & Tyagi S C (2008) Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. Am J Physiol Endocrinol Metab 295, 1205-1212
45. Bordet R, Gelé P, Duriez P & Fruchart J C (2006) PPARs: a new target for neuroprotection. J Neurol Neurosurg Psychiatr 77, 285-287
46. Heneka M T, Landreth G E & Feinstein D L (2001) Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. Ann Neurol 49, 276
47. Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, Zanetti O & Rossini P M (2009) A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res 21, 102-110
48. de D, Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G & Kremer B (2008) No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One 3, 1475
49. Heneka M T, Wiesinger H, Dumitrescu-Ozimek L, Riederer P, Feinstein D L & Klockgether T (2001) Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol 60(9), 906-916
50. Combs C K, Johnson D E, Karlo J C, Cannady S B & Landreth G E (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20, 558-567
51. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A & Perez-Castillo A (2005) Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 280, 21453-21462
52. Hirsch E C, Breidert T, Rousselet E, Hunot S, Hartmann A & Michel P P (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann NY Acad Sci 991, 214-228
53. Breidert T, Callebert J, Heneka M T, Landreth G, Launay J M & Hirsch E C (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82, 615-624
54. Dehmer T, Heneka M T, Sastre M, Dichgans J & Schulz J B (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88, 494-501
55. Schintu N, Frau, Abba M, Caboni M, Garau A, Caboni E & Carta A R (2009) PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 29, 954-963
56. Chen H, Jacobs E, Schwarzschild M A, McCullough M L, Calle E E, Thun M J & Ascherio A (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58, 963-967
57. Lehmann J M, Lenhard J M, Oliver B B, Ringold G M & Kliewer S M (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272, 3406-3410
58. Martin R, Mcfarland H F & Mcfarlin D E (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10, 153-187
59. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala R K, Westin S, Hoffmann A, Subramaniam S, David M, Rosenfeld M G Glass C K (2005) Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122, 707-721
60. Jiang C, Ting A T & Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86
61. Ricote M, Li A C, Willson T M, Kelly C J & Glass C K (1998) The peroxisome proliferator-activated receptorgamma is a negative regulator of macrophage activation. Nature 391, 79-82
62. Diab A, Deng C, Smith J D, Hussain J C, Phanavanh B, Lovett-Racke A E, Drew P D & Racke M K (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 168, 2508-2515
63. Hofstetter H H, Ibrahim S M, Koczan D, Kruse N, Weishaupt A, Toyka K V & Gold R (2005) Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 237, 123-130
64. Charo I F & Ransohoff R M (2006) The many roles of chemokines and chemokine receptors in inflammation. New Engl J Med 354, 610-612
65. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna R A S, Graf K, Fleck E, Hsueh W A & Law R E (2000) Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 401, 259-270
66. Ou Z, Zhao X, Labiche L A, Strong R, Grotta J C, Herrmann O & Aronowski J (2006) Neuronal expression of peroxisome proliferator-activated receptor-γ (PPARγ) and 15d-prostaglandin J2-mediated protection of brain after experimental cerebral ischemia in rat. Brain Res 1096, 196-203